A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy
Public ClinicalTrials.gov record NCT00823992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Taspoglutide on Glycemic Control, and Its Safety and Tolerability, in Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This 2 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to placebo in obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Patients will be randomized to receive taspoglutide (10mg sc once weekly for 4 weeks followed by 20mg once weekly) or placebo sc, in addition to their prescribed, pre-existing metformin therapy.After the first 24 weeks, patients on placebo will be switched to taspoglutide 20mg once weekly (after 4 weeks on taspoglutide 10mg once weekly) The anticipated time on study treatment is 12 months, and the target sample size is 100-500 individuals.
Study identification
- NCT ID
- NCT00823992
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 305 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2009 (Type not available)
- Primary completion
- May 2010 (Actual)
- Completion
- May 2010 (Actual)
- Last update posted
- Jul 28, 2016
2009 – 2010
United States locations
- U.S. sites
- 29
- U.S. states
- 18
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Bermuda Dunes | California | 92203 | — |
| Not listed | La Jolla | California | 92037 | — |
| Not listed | Los Angeles | California | 90057 | — |
| Not listed | Mission Viejo | California | 92691 | — |
| Not listed | Brooksville | Florida | 34601 | — |
| Not listed | Miami | Florida | 33133 | — |
| Not listed | St. Petersburg | Florida | 33709 | — |
| Not listed | Atlanta | Georgia | 30342 | — |
| Not listed | Chicago | Illinois | 60607 | — |
| Not listed | Avon | Indiana | 46123 | — |
| Not listed | New Orleans | Louisiana | 70121 | — |
| Not listed | Bangor | Maine | 04401 | — |
| Not listed | Royal Oak | Michigan | 48073 | — |
| Not listed | Picayune | Mississippi | 39466 | — |
| Not listed | Clifton | New Jersey | 07012 | — |
| Not listed | Toms River | New Jersey | 08753 | — |
| Not listed | Albuquerque | New Mexico | 87131 | — |
| Not listed | New York | New York | 10025 | — |
| Not listed | Springfield Gardens | New York | 11413 | — |
| Not listed | Charlotte | North Carolina | 28277 | — |
| Not listed | Shelby | North Carolina | 28150 | — |
| Not listed | Norman | Oklahoma | 73069 | — |
| Not listed | Medford | Oregon | 97504 | — |
| Not listed | Clinton | South Carolina | 29325 | — |
| Not listed | Kingsport | Tennessee | 37660 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Houston | Texas | 77074 | — |
| Not listed | Midland | Texas | 79707 | — |
| Not listed | San Antonio | Texas | 78237 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00823992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2016 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00823992 live on ClinicalTrials.gov.